Treating chronic hepatitis B infection in patients who are pregnant or are undergoing immunosuppressive chemotherapy

Seminars in Liver Disease

Volumn 27, Issue SUPPL. 1, 2007, Pages 18-24

  Terrault, Norah A ^a   Jacobson, Ira M ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Chemotherapy; Hepatitis B; Immunosuppressive therapy; Nucleoside inhibitors; Pregnancy; Vertical transmission

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

CLINICAL TRIAL; CONFERENCE PAPER; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOPROPHYLAXIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; MEDICAL SOCIETY; PREGNANCY; PRIORITY JOURNAL; TREATMENT PLANNING; VERTICAL TRANSMISSION;

ADULT; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BREAST NEOPLASMS; FEMALE; HEPATITIS B, CHRONIC; HUMANS; IMMUNOCOMPROMISED HOST; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 34548138876     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-984696     Document Type: Conference Paper

References (29)

1. Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006;4:936-962
2. Lok AS, McMahon BJ; Practice Guidelines Committee, American Association for the Study of Liver Diseases (AASLD). Chronic hepatitis B. Hepatology 2007;45:507-539
3. Kohrt HE, Ouyang DL, Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 2006;24:1003-1016
4. Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006;131:59-68
5. Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1 - immunization of infants, children, and adolescents. MMWR Recomm Rep 2005;54:1-31
6. Dore GJ, Guan R, Wasim Jafri SM, et al. Management of chronic hepatitis B in challenging patient populations. Liver Int 2006;26(suppl 2):38-46
7. Zhang SL, Yue YF, Bai GQ, et al. Mechanism of intrauterine infection of hepatitis B virus. World J Gastroenterol 2004;10:437-438
8. del Canho R, Grosheide PM, Mazel JA, et al. Ten-year neonatal hepatitis B vaccination program, The Netherlands, 1982-1992: protective efficacy and long-term immunogenicity. Vaccine 1997;15:1624-1630
9. Ngui SL, Andrews NJ, Underhill GS, et al. Failed postnatal immunoprophylaxis for hepatitis B: characteristics of maternal hepatitis B virus as risk factors. Clin Infect Dis 1998;27:100-106
10. van Zonneveld M, van Nunen AB, Niesters HG, et al. Lamivudine treatment during pregnancy to prevent perinatal transmission of hepatitis B virus infection. J Viral Hepat 2003;10:294-297
11. Yeo W, Zee B, Zhong S, et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer 2004;90:1306-1311
12. Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 2000;62:299-307
13. Hui CK, Cheung WW, Au WY, et al. Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 2005;54:1597-1603
14. Li YH, He YF, Jiang WQ, et al. Lamivudine prophylaxis reduces the incidence and severity of hepatitis in hepatitis B virus carriers who receive chemotherapy for lymphoma. Cancer 2006;106:1320-1325
15. Dai MS, Wu PF, Shyu RY, et al. Hepatitis B virus reactivation in breast cancer patients undergoing cytotoxic chemotherapy and the role of preemptive lamivudine administration. Liver Int 2004;24:540-546
16. Idilman R, Arat M, Soydan E, et al. Lamivudine prophylaxis for prevention of chemotherapy-induced hepatitis B virus reactivation in hepatitis B virus carriers with malignancies. J Viral Hepat 2004;11:141-147
17. Yeo W, Ho WM, Hui P, et al. Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patients. Breast Cancer Res Treat 2004;88:209-215
18. Yeo W, Hui EP, Chan AT, et al. Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol 2005;28:379-384
19. Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125:1742-1749
20. Lee GW, Ryu MH, Lee JL, et al. The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with non-Hodgkin's lymphoma who receive cytotoxic chemotherapy. J Korean Med Sci 2003;18:849-854
21. Sera T, Hiasa Y, Michitaka K, et al. Anti-HBs-positive liver failure due to hepatitis B virus reactivation induced by rituximab. Intern Med 2006;45:721-724
22. Xu W-M, Cui Y-T, Wang L, et al. Efficacy and safety of lamivudine in late pregnancy for the prevention of mother-child transmission of hepatitis B: a multicentre, randomised, double-blind, placebo-controlled study. Hepatology 2004;40(suppl 4):272A. Abstract 246
23. Idenix Pharmaceuticals. TYZEKA (telbivudine) tablets prescribing information. Available at: https://www.tyzeka.com/default.asp?page= prescribing_information. Accessed December 20, 2006
24. Ross B. Safety of antiviral therapy of chronic hepatitis B during pregnancy. Presented at: National Institutes of Health Hepatitis B Workshop; April 6-8, 2006; Bethesda, MD
25. Kuo A, Dienstag JL, Chung RT. Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant hepatitis B. Clin Gastroenterol Hepatol 2004;2:266-272
26. van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421-1425
27. The Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 January 2006. Wilmington, NC: Registry Coordinating Center; 2006. Available at: http://www.apregistry.com/forms/apr_report_106.pdf. Accessed December 20, 2006
28. Centers for Disease Control and Prevention (CDC). Improved national prevalence estimates for 18 selected major birth defects - United States, 1999-2001. MMWR Morb Mortal Wkly Rep 2006;54:1301-1305
29. Millonig G, Kern M, Ludwiczek O, et al. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 2006;12:974-976